Investor Highlights

Half Year Report - 31 December 2018

Pharmaxis Ltd financial and directors' reports for the six months ended 31 December 2018

Read report – pdf

Shareholder Update - December 2018

Shareholder update for the quarter ended 31 December 2018

Read quarterly update - pdf

Pharmaxis Announces LOXL2 Inhibitor Program is Phase 2 Ready Following Completion of 13 Week Toxicity Studies

Pharmaceutical research company Pharmaxis (ASX: PXS) today announced that it has now received reports on all of the 13-week toxicity studies conducted for each of its two Lysyl Oxidase Like 2 (LOXL2) inhibitors. Together with the previously released results of Pharmaxis phase 1 clinical trials for both compounds showing best in class target engagement from a once a day oral dose, Pharmaxis believes that this program is now ready to enter phase 2 clinical studies for fibrotic diseases such as Non‐Alcoholic Steatohepatitis (NASH), cardiac fibrosis and Idiopathic Pulmonary Fibrosis (IPF).

Read full media release - pdf

CEO Presentation to 2018 AGM

Presentation by the Pharmaxis CEO and CFO to the 2018 AGM

View presentation – pdf

2018 Annual Report

2018 Statutory Annual Report

Read report – pdf